Replies to post #118166 on Amarantus Bioscience Holdings Inc (AMBS)

[brharris]

Thanks for the highlights on the presentation. Having had a chance to listen yet. Good news today and sounds like more on the way. The quiet period seems to be over.

[redspeed]

- 3 orphans and two more on the way. A year ago none.

Make that 3 orphans to date and potentially 3 other ones including Wolfram

Potential paradigm shift in cell protection and restoration
-Collaboration w/ Buck Institute yielding tremendous results
-75+ peer-reviewed publications

•Multi-billion dollar opportunity: Breakthrough science

•Potential in other indications
-Wolfram’s (potential orphan)
-Parkinson’s
-Diabetes
-Myocardial infarction
-Hearing loss (potential orphan)
-Otology
-Other apoptosis-related disorders

Upcoming Milestones
- Commence first-in-human Phase 1 study in 2H 2016
- Expand development program into additional high-value indications

[JPetroInc]

everything aside, all it takes is one

to make it over the finish line

and the game changes on a NY dime

just maybe, there is enough compelling and immediate advancements on ESS to warranted freezing all programs - putting the emergency brakes on all programs for the sake of 1 is not only strange, but highly unusual...



just wish a reputable IB would agree with Geralds personal pipe assesment of:

"We remain supremely confident in the strength of our pipeline."

when:

1.) all programs outside ESS are now stalled
2.) AMBS mantra of "eltoprazine is the Company’s lead therapeutic program" has radically changed
3.) they just signed more floorless toxic death spiral convertibles after a massive RS and AS increase to 3.3-Bil. pre-RS
4.) we've all heard this false story many times before of 'it just around the corner'

this continues to wreak of "going it alone" which is all fine and a greater reward for the shareholders in the long run - but also increases the risk if they fail - something which we all just bitterly witnessed with the Series G conversions, $1 shareprice and paultry 9-Mil. Market Cap